Literature DB >> 16388913

Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice.

D S Kim1, R D Palmiter, A Cummins, C R Gerfen.   

Abstract

Lesions of dopaminergic nigrostriatal neurons cause supersensitivity to dopamine in the striatum. Previous work has shown that such supersensitivity, an important aspect of rodent models of Parkinson's disease, is associated with anatomically abnormal patterns in the activation of extracellular signal-regulated kinase. After lesions of dopaminergic neurons, dopamine D1-receptor agonists activate extracellular signal-regulated kinase in the dorsal striatum, something not observed in intact animals. Here we used a more selective method of dopamine depletion. Dopamine-deficient mice, in which the tyrosine hydroxylase gene is specifically inactivated in dopaminergic neurons, were used to investigate dopamine D1-receptor-mediated activation of extracellular signal-regulated kinase. In wild-type mice, acute treatment with a dopamine D1-receptor agonist results in activation of extracellular signal-regulated kinase in the nucleus accumbens without activation in the dorsal striatum. In contrast, in dopamine-deficient mice, dopamine D1-receptor-agonist treatment results in activation of extracellular signal-regulated kinase not only in the nucleus accumbens, but also throughout most of the dorsal striatum. Chronic replacement of dopamine by repeated injection of L-DOPA for 36 h reverses this supersensitive extracellular signal-regulated kinase activation. This reversal displays a dorsal to ventral progression such that, by 36 h, extracellular signal-regulated kinase activation is virtually restricted to the nucleus accumbens, as in wild-type mice. The reversal of dopamine D1-receptor activation of extracellular signal-regulated kinase in dopamine-deficient mice following chronic L-DOPA treatment shows that the lack of dopamine, rather than absence of other factors secreted from dopaminergic neurons, is responsible for dopamine supersensitivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388913     DOI: 10.1016/j.neuroscience.2005.10.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

1.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

Review 2.  Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.

Authors:  Gabriel Henrique Hawthorne; Marcelo Picinin Bernuci; Mariza Bortolanza; Vitor Tumas; Ana Carolina Issy; Elaine Del-Bel
Journal:  Neurotox Res       Date:  2016-08-31       Impact factor: 3.911

3.  Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Seunghyi Kook; Lilia Zurkovsky; Kevin N Dalby; Eugenia V Gurevich
Journal:  Exp Neurol       Date:  2015-02-14       Impact factor: 5.330

4.  Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.

Authors:  Ayse Ulusoy; Gurdal Sahin; Deniz Kirik
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 5.  G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Authors:  Eugenia V Gurevich; Raul R Gainetdinov; Vsevolod V Gurevich
Journal:  Pharmacol Res       Date:  2016-05-10       Impact factor: 7.658

6.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

Authors:  Emanuela Santini; Veronique Sgambato-Faure; Qin Li; Marc Savasta; Sandra Dovero; Gilberto Fisone; Erwan Bezard
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

Review 8.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

9.  Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.

Authors:  David Lindenbach; Kristin B Dupre; Karen L Eskow Jaunarajs; Corinne Y Ostock; Adam A Goldenberg; Christopher Bishop
Journal:  Brain Res       Date:  2013-09-21       Impact factor: 3.252

Review 10.  A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling.

Authors:  Valerie Z Wall; Jones G Parker; Jonathan P Fadok; Martin Darvas; Larry Zweifel; Richard D Palmiter
Journal:  Mol Cell Neurosci       Date:  2010-10-01       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.